JP2023502992A - 改良された移動防止特性を有するステント - Google Patents
改良された移動防止特性を有するステント Download PDFInfo
- Publication number
- JP2023502992A JP2023502992A JP2022528600A JP2022528600A JP2023502992A JP 2023502992 A JP2023502992 A JP 2023502992A JP 2022528600 A JP2022528600 A JP 2022528600A JP 2022528600 A JP2022528600 A JP 2022528600A JP 2023502992 A JP2023502992 A JP 2023502992A
- Authority
- JP
- Japan
- Prior art keywords
- flange
- outer diameter
- stent
- flange portion
- tubular body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000013508 migration Methods 0.000 title description 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- 208000037804 stenosis Diseases 0.000 claims description 15
- 230000036262 stenosis Effects 0.000 claims description 15
- 230000007704 transition Effects 0.000 claims description 9
- 239000000463 material Substances 0.000 description 63
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 50
- 229910001000 nickel titanium Inorganic materials 0.000 description 39
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 33
- -1 poly(L-lactide) Polymers 0.000 description 32
- 229920000642 polymer Polymers 0.000 description 27
- 229910052697 platinum Inorganic materials 0.000 description 25
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 15
- 229910052737 gold Inorganic materials 0.000 description 15
- 239000010931 gold Substances 0.000 description 15
- 229910052715 tantalum Inorganic materials 0.000 description 14
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 14
- 239000002131 composite material Substances 0.000 description 13
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 12
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 12
- 229920001432 poly(L-lactide) Polymers 0.000 description 12
- 239000010936 titanium Substances 0.000 description 12
- 229910052719 titanium Inorganic materials 0.000 description 12
- 229910045601 alloy Inorganic materials 0.000 description 11
- 239000000956 alloy Substances 0.000 description 11
- 229910001220 stainless steel Inorganic materials 0.000 description 10
- 229920001610 polycaprolactone Polymers 0.000 description 9
- 239000004632 polycaprolactone Substances 0.000 description 9
- 229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 239000010935 stainless steel Substances 0.000 description 8
- 229910000531 Co alloy Inorganic materials 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 7
- 229910052721 tungsten Inorganic materials 0.000 description 7
- 239000010937 tungsten Substances 0.000 description 7
- 229910001182 Mo alloy Inorganic materials 0.000 description 6
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 6
- 229910052788 barium Inorganic materials 0.000 description 6
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 6
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 6
- 229910052797 bismuth Inorganic materials 0.000 description 6
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 6
- 229910052758 niobium Inorganic materials 0.000 description 6
- 239000010955 niobium Substances 0.000 description 6
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 6
- 229920001245 poly(D,L-lactide-co-caprolactone) Polymers 0.000 description 6
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 6
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 6
- 239000004810 polytetrafluoroethylene Substances 0.000 description 6
- 239000004814 polyurethane Substances 0.000 description 6
- 229920002635 polyurethane Polymers 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000003466 welding Methods 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 5
- 239000004743 Polypropylene Substances 0.000 description 5
- 229920000728 polyester Polymers 0.000 description 5
- 229920001155 polypropylene Polymers 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000004952 Polyamide Substances 0.000 description 4
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 239000000560 biocompatible material Substances 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 229910000856 hastalloy Inorganic materials 0.000 description 4
- 229920002647 polyamide Polymers 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 239000005020 polyethylene terephthalate Substances 0.000 description 4
- 229920000106 Liquid crystal polymer Polymers 0.000 description 3
- 239000004977 Liquid-crystal polymers (LCPs) Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229920002614 Polyether block amide Polymers 0.000 description 3
- 239000004721 Polyphenylene oxide Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052741 iridium Inorganic materials 0.000 description 3
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 229910000734 martensite Inorganic materials 0.000 description 3
- 239000007769 metal material Substances 0.000 description 3
- 238000009740 moulding (composite fabrication) Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920006209 poly(L-lactide-co-D,L-lactide) Polymers 0.000 description 3
- 229920006210 poly(glycolide-co-caprolactone) Polymers 0.000 description 3
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 3
- 229920002627 poly(phosphazenes) Polymers 0.000 description 3
- 239000000622 polydioxanone Substances 0.000 description 3
- 229920002643 polyglutamic acid Polymers 0.000 description 3
- 229920000098 polyolefin Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000012781 shape memory material Substances 0.000 description 3
- 241000473391 Archosargus rhomboidalis Species 0.000 description 2
- 229910000881 Cu alloy Inorganic materials 0.000 description 2
- 229940123011 Growth factor receptor antagonist Drugs 0.000 description 2
- 229920000339 Marlex Polymers 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000004696 Poly ether ether ketone Substances 0.000 description 2
- 239000004697 Polyetherimide Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- 239000004734 Polyphenylene sulfide Substances 0.000 description 2
- 229910001080 W alloy Inorganic materials 0.000 description 2
- MTHLBYMFGWSRME-UHFFFAOYSA-N [Cr].[Co].[Mo] Chemical compound [Cr].[Co].[Mo] MTHLBYMFGWSRME-UHFFFAOYSA-N 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000004019 antithrombin Chemical class 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000788 chromium alloy Substances 0.000 description 2
- PRQRQKBNBXPISG-UHFFFAOYSA-N chromium cobalt molybdenum nickel Chemical compound [Cr].[Co].[Ni].[Mo] PRQRQKBNBXPISG-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229920006351 engineering plastic Polymers 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- DDTIGTPWGISMKL-UHFFFAOYSA-N molybdenum nickel Chemical compound [Ni].[Mo] DDTIGTPWGISMKL-UHFFFAOYSA-N 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 description 2
- 229920002530 polyetherether ketone Polymers 0.000 description 2
- 229920001601 polyetherimide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 229920006380 polyphenylene oxide Polymers 0.000 description 2
- 229920000069 polyphenylene sulfide Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000005167 vascular cell Anatomy 0.000 description 2
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- OVGRCEFMXPHEBL-UHFFFAOYSA-N 1-ethenoxypropane Chemical compound CCCOC=C OVGRCEFMXPHEBL-UHFFFAOYSA-N 0.000 description 1
- VNDNKFJKUBLYQB-UHFFFAOYSA-N 2-(4-amino-6-chloro-5-oxohexyl)guanidine Chemical compound ClCC(=O)C(N)CCCN=C(N)N VNDNKFJKUBLYQB-UHFFFAOYSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 229920004943 Delrin® Polymers 0.000 description 1
- 229920006055 Durethan® Polymers 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 229910000640 Fe alloy Inorganic materials 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229920003620 Grilon® Polymers 0.000 description 1
- 229910000787 Gum metal Inorganic materials 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 229920000271 Kevlar® Polymers 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229920000914 Metallic fiber Polymers 0.000 description 1
- 229910000792 Monel Inorganic materials 0.000 description 1
- 229910000990 Ni alloy Inorganic materials 0.000 description 1
- 229920000299 Nylon 12 Polymers 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920000265 Polyparaphenylene Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- QXZUUHYBWMWJHK-UHFFFAOYSA-N [Co].[Ni] Chemical compound [Co].[Ni] QXZUUHYBWMWJHK-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- YOCUPQPZWBBYIX-UHFFFAOYSA-N copper nickel Chemical compound [Ni].[Cu] YOCUPQPZWBBYIX-UHFFFAOYSA-N 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940124642 endogenous agent Drugs 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- QHSJIZLJUFMIFP-UHFFFAOYSA-N ethene;1,1,2,2-tetrafluoroethene Chemical group C=C.FC(F)=C(F)F QHSJIZLJUFMIFP-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- MSKQYWJTFPOQAV-UHFFFAOYSA-N fluoroethene;prop-1-ene Chemical group CC=C.FC=C MSKQYWJTFPOQAV-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229910001026 inconel Inorganic materials 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- UGKDIUIOSMUOAW-UHFFFAOYSA-N iron nickel Chemical compound [Fe].[Ni] UGKDIUIOSMUOAW-UHFFFAOYSA-N 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229920000092 linear low density polyethylene Polymers 0.000 description 1
- 239000004707 linear low-density polyethylene Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 239000002905 metal composite material Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- MOWMLACGTDMJRV-UHFFFAOYSA-N nickel tungsten Chemical compound [Ni].[W] MOWMLACGTDMJRV-UHFFFAOYSA-N 0.000 description 1
- 229910000623 nickel–chromium alloy Inorganic materials 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000011112 polyethylene naphthalate Substances 0.000 description 1
- 229920000417 polynaphthalene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002215 polytrimethylene terephthalate Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- MHSKRLJMQQNJNC-UHFFFAOYSA-N terephthalamide Chemical compound NC(=O)C1=CC=C(C(N)=O)C=C1 MHSKRLJMQQNJNC-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 239000003803 thymidine kinase inhibitor Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2002/044—Oesophagi or esophagi or gullets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/848—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
- A61F2002/8486—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs provided on at least one of the ends
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0095—Saddle-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0039—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in diameter
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Prostheses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
追加的に又は代替的に、展開形態では、第2のフランジ部分は、第2の端部に近接する第3のフランジと、第3のフランジから第1の端部に向かって長手方向に離隔した第4のフランジとから構成され得る。
追加的に又は代替的に、展開形態では、第1のフランジ部分は、第1の半径方向内向き力に抵抗するように構成することができ、第2のフランジ部分は、第2の半径方向内向き力に抵抗するように構成することができ、サドル部分は、第1の半径方向内向き力及び第2の半径方向内向き力よりも小さい第3の半径方向内向き力に抵抗するように構成することができる。
追加的に又は代替的に、展開形態では、第3の半径方向内向き力は、第1の半径方向内向き力又は第2の半径方向内向き力の75%未満であり得る。
追加的に又は代替的に、管状本体の少なくとも一部は、カバー部材を含み得る。
追加的に又は代替的に、展開形態では、第1のフランジ部分は、第1の端部に近接する第1のフランジと、第1のフランジから第2の端部に向かって長手方向に離隔した第2のフランジとから構成され得る。
追加的に又は代替的に、展開形態では、第2のフランジ部分は、第2の端部に近接する第3のフランジと、第3のフランジから第1の端部に向かって長手方向に離隔した第4のフランジとから構成され得る。
追加的に又は代替的に、展開形態では、第2の外径は、第1の外径の10%以内であり得る。
追加的に又は代替的に、管状本体の少なくとも一部は、カバー部材を含み得る。
本明細書では、明示的に示されているか否かに関わらず、すべての数値は、「約」という用語によって修飾されているものと想定する。数値の文脈における「約」という用語は、概して、当業者が列挙された値に等価であるとみなす(例えば、同じ機能又は結果を有する)数字の範囲を指す。多くの場合、「約」という用語は、最も近い有効数字に四捨五入された数字を含む可能性がある。(例えば、数値以外の文脈における)「約」という用語の他の使用は、別段の指定がない限り、本明細書の文脈から理解され且つ文脈に一貫するような、それらの通常の慣習的な定義を有するものと想定され得る。
さまざまな構成要素、特徴及び/又は仕様に関するいくつかの好適な寸法、範囲及び/又は値を開示するが、本開示によって示唆を受ける当業者は、所望の寸法、範囲及び/又は値が明示的に開示されているものから外れる場合があることを理解するであろう。
Claims (15)
- 体管腔内の狭窄部にわたるように構成されたステントであって、
該ステントは送達形態と展開形態との間で移行するように構成された管状本体を備え、該管状本体は第1の端部及び第2の端部を有し、
前記展開形態では、
前記管状本体は、前記第1の端部に近接する第1のフランジ部分と、前記第2の端部に近接する第2のフランジ部分と、前記第1のフランジ部分から前記第2のフランジ部分まで延びるサドル部分とを画定し、
前記管状本体は、前記第1の端部から前記第2の端部まで延びる全長をさらに画定し、
前記サドル部分は外径を有し、前記第1のフランジ部分が第1の外径を有し、前記第2のフランジ部分が第2の外径を有し、
前記第1の外径が、前記サドル部分の前記外径よりも大きく、
前記第2の外径が、前記サドル部分の前記外径よりも大きく、
前記サドル部分の長手方向長さが、前記管状本体の前記全長の少なくとも50%である、
ステント。 - 前記展開形態では、前記第1のフランジ部分が、第1の半径方向内向き力に抵抗するように構成され、前記第2のフランジ部分が、第2の半径方向内向き力に抵抗するように構成され、前記サドル部分が、前記第1の半径方向内向き力及び前記第2の半径方向内向き力よりも小さい第3の半径方向内向き力に抵抗するように構成される、請求項1に記載のステント。
- 前記展開形態では、前記第1の半径方向内向き力が、前記第2の半径方向内向き力の10%以内である、請求項2に記載のステント。
- 前記展開形態では、前記第3の半径方向内向き力が、前記第1の半径方向内向き力又は前記第2の半径方向内向き力の75%未満である、請求項2又は3に記載のステント。
- 前記展開形態では、前記サドル部分の前記長手方向長さが、前記管状本体の前記全長の少なくとも75%である、請求項1~4のいずれか一項に記載のステント。
- 前記サドル部分が、前記第1のフランジ部分から前記第2のフランジ部分に向かって延びる第1の半径方向内向きテーパを含む、請求項1~5のいずれか一項に記載のステント。
- 前記展開形態では、前記サドル部分が、前記第2のフランジ部分から前記第1のフランジ部分に向かって延びる第2の半径方向内向きテーパを含む、請求項6に記載のステント。
- 前記展開形態では、前記第1のフランジ部分が、前記第1の端部に近接する第1のフランジと、前記第1のフランジから前記第2の端部に向かって長手方向に離隔した第2のフランジとで構成される、請求項1~7のいずれか一項に記載のステント。
- 前記展開形態では、前記第2のフランジが、約5mm~約10mmだけ前記第1のフランジから離隔する、請求項8に記載のステント。
- 前記展開形態では、前記第2のフランジ部分が、前記第2の端部に近接する第3のフランジと、前記第3のフランジから前記第1の端部に向かって長手方向に離隔した第4のフランジとで構成される、請求項1~9のいずれか一項に記載のステント。
- 前記展開形態では、前記第4のフランジが、約5mm~約10mmだけ前記第3のフランジから離隔する、請求項10に記載のステント。
- 前記展開形態では、前記第2の外径が、前記第1の外径の10%以内である、請求項1~11のいずれか一項に記載のステント。
- 前記展開形態では、前記第2の外径が、前記第1の外径の5%以内である、請求項1~12のいずれか一項に記載のステント。
- 前記管状本体の少なくとも一部が、カバー部材を含む、請求項1~13のいずれか一項に記載のステント。
- 体管腔内で狭窄部を治療する方法であって、
該方法は、前記体管腔内においてステントを送達形態で位置決めすることを備え、該位置決めすることは、前記ステントのサドル部分が前記狭窄部にわたり、第1のフランジ部分が前記狭窄部の近位側にあり、第2のフランジ部分が前記狭窄部の遠位側にある状態で、前記ステントが位置決めされ、
該方法は、前記ステントを前記送達形態から展開形態に移行させることを備え、
前記展開形態では、
前記第1のフランジ部分が、前記サドル部分の外径よりも大きい第1の外径を有し、
前記第2のフランジ部分が、前記サドル部分の外径よりも大きい第2の外径を有し、
前記第1のフランジ部分の第1のフランジと前記第1のフランジから長手方向に離隔した前記第1のフランジ部分の第2のフランジとが、それらの間に前記体管腔の壁の第1の部分を捕捉して、前記狭窄部に隣接して前記ステントを固定し、
前記第2のフランジ部分の第3のフランジと前記第3のフランジから長手方向に離隔した前記第2のフランジ部分の第4のフランジとが、それらの間に前記体管腔の壁の第2の部分を捕捉して、前記狭窄部に隣接して前記ステントを固定する、
方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962936922P | 2019-11-18 | 2019-11-18 | |
US62/936,922 | 2019-11-18 | ||
PCT/US2020/060839 WO2021101861A1 (en) | 2019-11-18 | 2020-11-17 | Stent with improved anti-migration properties |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023502992A true JP2023502992A (ja) | 2023-01-26 |
JP7411800B2 JP7411800B2 (ja) | 2024-01-11 |
Family
ID=73790290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022528600A Active JP7411800B2 (ja) | 2019-11-18 | 2020-11-17 | 改良された移動防止特性を有するステント |
Country Status (6)
Country | Link |
---|---|
US (2) | US11564787B2 (ja) |
EP (1) | EP4061291A1 (ja) |
JP (1) | JP7411800B2 (ja) |
KR (1) | KR20220098193A (ja) |
CN (1) | CN114929165A (ja) |
WO (1) | WO2021101861A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2967829B1 (en) * | 2013-03-15 | 2017-04-26 | Boston Scientific Scimed, Inc. | Anti-migration micropatterned stent coating |
EP4185239A1 (en) * | 2020-07-24 | 2023-05-31 | Merit Medical Systems, Inc. | Esophageal stents and related methods |
WO2022093710A1 (en) | 2020-10-26 | 2022-05-05 | Merit Medical Systems, Inc. | Esophageal stents with helical thread |
US20230329887A1 (en) * | 2022-04-18 | 2023-10-19 | Boston Scientific Scimed Inc. | Multiple flare and shoulder anti migration stent |
US20240016636A1 (en) * | 2022-07-14 | 2024-01-18 | Boston Scientific Scimed, Inc. | Progressively expanding anti-migration stent |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180280166A1 (en) * | 2017-03-30 | 2018-10-04 | Boston Scientific Scimed, Inc. | Stents with dual tissue-wall anchoring features |
US20180338846A1 (en) * | 2017-05-25 | 2018-11-29 | Boston Scientific Scimed, Inc. | Devices and methods for multi-lumen access and drainage |
US20190099589A1 (en) * | 2017-10-03 | 2019-04-04 | Boston Scientific Scimed, Inc. | Flow control stent |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7101392B2 (en) | 1992-03-31 | 2006-09-05 | Boston Scientific Corporation | Tubular medical endoprostheses |
ES2135520T3 (es) * | 1993-11-04 | 1999-11-01 | Bard Inc C R | Protesis vascular no migrante. |
US5725552A (en) | 1994-07-08 | 1998-03-10 | Aga Medical Corporation | Percutaneous catheter directed intravascular occlusion devices |
US5846261A (en) | 1994-07-08 | 1998-12-08 | Aga Medical Corp. | Percutaneous catheter directed occlusion devices |
US6123715A (en) | 1994-07-08 | 2000-09-26 | Amplatz; Curtis | Method of forming medical devices; intravascular occlusion devices |
US5575818A (en) | 1995-02-14 | 1996-11-19 | Corvita Corporation | Endovascular stent with locking ring |
BE1009278A3 (fr) | 1995-04-12 | 1997-01-07 | Corvita Europ | Tuteur auto-expansible pour dispositif medical a introduire dans une cavite d'un corps, et dispositif medical muni d'un tel tuteur. |
ATE218052T1 (de) | 1995-11-27 | 2002-06-15 | Schneider Europ Gmbh | Stent zur anwendung in einem körperlichen durchgang |
AU723785B2 (en) | 1996-02-02 | 2000-09-07 | Transvascular, Inc. | Methods and apparatus for connecting openings formed in adjacent blood vessels or other anatomical structures |
US6174330B1 (en) | 1997-08-01 | 2001-01-16 | Schneider (Usa) Inc | Bioabsorbable marker having radiopaque constituents |
US6264689B1 (en) | 1998-03-31 | 2001-07-24 | Scimed Life Systems, Incorporated | Low profile medical stent |
US7018401B1 (en) | 1999-02-01 | 2006-03-28 | Board Of Regents, The University Of Texas System | Woven intravascular devices and methods for making the same and apparatus for delivery of the same |
US7175644B2 (en) | 2001-02-14 | 2007-02-13 | Broncus Technologies, Inc. | Devices and methods for maintaining collateral channels in tissue |
US6585758B1 (en) | 1999-11-16 | 2003-07-01 | Scimed Life Systems, Inc. | Multi-section filamentary endoluminal stent |
US6468303B1 (en) | 2000-03-27 | 2002-10-22 | Aga Medical Corporation | Retrievable self expanding shunt |
US6620122B2 (en) | 2001-04-26 | 2003-09-16 | Scimed Life Systems, Inc. | Gastric pseudocyst drainage and stent delivery system for use therein |
US6663663B2 (en) | 2001-05-14 | 2003-12-16 | M.I. Tech Co., Ltd. | Stent |
US7115136B2 (en) | 2001-06-20 | 2006-10-03 | Park Medical Llc | Anastomotic device |
US7001425B2 (en) | 2002-11-15 | 2006-02-21 | Scimed Life Systems, Inc. | Braided stent method for its manufacture |
US7591845B2 (en) | 2003-02-19 | 2009-09-22 | Taewoong Medical Co., Ltd. | Stent for high frequency thermotherapy |
AU2003253446A1 (en) | 2003-07-29 | 2005-02-15 | Jin-Hong Kim | Self-expandable stent |
US7763011B2 (en) | 2003-12-22 | 2010-07-27 | Boston Scientific Scimed, Inc. | Variable density braid stent |
US8425539B2 (en) | 2004-04-12 | 2013-04-23 | Xlumena, Inc. | Luminal structure anchoring devices and methods |
EP2407127B1 (en) | 2004-11-10 | 2014-04-23 | Boston Scientific Scimed, Inc. | Atraumatic stent with reduced deployment force |
US20090270972A1 (en) * | 2006-05-23 | 2009-10-29 | All-Vascular Pty Ltd. | Endovenous valve transfer stent |
US20080109069A1 (en) * | 2006-11-07 | 2008-05-08 | Coleman James E | Blood perfusion graft |
US20090082803A1 (en) | 2007-09-26 | 2009-03-26 | Aga Medical Corporation | Braided vascular devices having no end clamps |
GB2476451A (en) | 2009-11-19 | 2011-06-29 | Cook William Europ | Stent Graft |
CA3010828A1 (en) | 2008-01-17 | 2009-07-23 | Boston Scientific Scimed, Inc. | Stent with anti-migration feature |
US8454632B2 (en) | 2008-05-12 | 2013-06-04 | Xlumena, Inc. | Tissue anchor for securing tissue layers |
US8114147B2 (en) | 2008-06-16 | 2012-02-14 | Boston Scientific Scimed, Inc. | Continuous double layered stent for migration resistance |
KR20100042478A (ko) | 2008-10-16 | 2010-04-26 | (주) 태웅메디칼 | 굴곡 변형성을 갖는 스텐트의 제조방법과 그 스텐트 |
US8151682B2 (en) | 2009-01-26 | 2012-04-10 | Boston Scientific Scimed, Inc. | Atraumatic stent and method and apparatus for making the same |
JP5535313B2 (ja) | 2009-05-29 | 2014-07-02 | エックスルミナ, インコーポレイテッド | 隣接する組織層にわたってステントを展開するための装置および方法 |
CN201578402U (zh) | 2009-11-16 | 2010-09-15 | 南京微创医学科技有限公司 | 能精确定位的支架置入器 |
US20130018215A1 (en) * | 2011-01-18 | 2013-01-17 | Merit Medical Systems, Inc. | Esophageal stent and methods for use of same |
KR101311756B1 (ko) | 2011-07-06 | 2013-09-26 | 신경민 | 인체 기관의 인접 조직 연결 시술용 스텐트 |
CN102488579A (zh) | 2011-12-14 | 2012-06-13 | 南京微创医学科技有限公司 | 混合式结构管腔内可回收支架 |
CZ2016799A3 (cs) | 2014-06-18 | 2017-09-13 | Xlumena, Inc. | Biliární stenty |
US10219921B2 (en) | 2014-10-02 | 2019-03-05 | Boston Scientific Scimed, Inc. | Controlled ingrowth feature for antimigration |
US11135050B2 (en) * | 2016-10-04 | 2021-10-05 | Boston Scientific Scimed, Inc. | Stent including anchoring members |
CN110381897A (zh) | 2016-12-29 | 2019-10-25 | 波士顿科学国际有限公司 | 用于将支架装载至递送装置中的方法 |
EP3565510B1 (en) * | 2017-03-06 | 2020-07-08 | Cardiovascular Lab S.p.A. O Brevemente Cv Lab S.p.A | Multilayer luminal endoprosthesis assembly and manufacturing method |
US11207200B2 (en) * | 2017-11-15 | 2021-12-28 | Hemodynamx-Technologies Ltd. | Aortic pressure loss reduction apparatus and methods |
EP3890662A1 (en) | 2018-12-04 | 2021-10-13 | Boston Scientific Scimed Inc. | Device for anastomotic bypass |
-
2020
- 2020-11-17 EP EP20821549.1A patent/EP4061291A1/en active Pending
- 2020-11-17 WO PCT/US2020/060839 patent/WO2021101861A1/en unknown
- 2020-11-17 JP JP2022528600A patent/JP7411800B2/ja active Active
- 2020-11-17 US US16/950,012 patent/US11564787B2/en active Active
- 2020-11-17 CN CN202080092310.4A patent/CN114929165A/zh active Pending
- 2020-11-17 KR KR1020227019214A patent/KR20220098193A/ko not_active Application Discontinuation
-
2022
- 2022-12-22 US US18/145,583 patent/US20230130924A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180280166A1 (en) * | 2017-03-30 | 2018-10-04 | Boston Scientific Scimed, Inc. | Stents with dual tissue-wall anchoring features |
US20180338846A1 (en) * | 2017-05-25 | 2018-11-29 | Boston Scientific Scimed, Inc. | Devices and methods for multi-lumen access and drainage |
US20190099589A1 (en) * | 2017-10-03 | 2019-04-04 | Boston Scientific Scimed, Inc. | Flow control stent |
Also Published As
Publication number | Publication date |
---|---|
CN114929165A (zh) | 2022-08-19 |
WO2021101861A1 (en) | 2021-05-27 |
KR20220098193A (ko) | 2022-07-11 |
EP4061291A1 (en) | 2022-09-28 |
US11564787B2 (en) | 2023-01-31 |
US20210145563A1 (en) | 2021-05-20 |
US20230130924A1 (en) | 2023-04-27 |
JP7411800B2 (ja) | 2024-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7411800B2 (ja) | 改良された移動防止特性を有するステント | |
CA3142835C (en) | Covered endoprosthesis with improved branch access | |
EP3773363B1 (en) | Stent delivery system with reduced deployment force | |
US20240024025A1 (en) | Devices and methods for inducing ablation in or around occluded implants | |
US11364030B2 (en) | Medical device for treating esophageal atresia | |
US20240065864A1 (en) | Endoprosthesis and methods for treating non-thrombotic iliac vein lesions | |
US11918496B2 (en) | Stent with improved deployment characteristics | |
US20220304795A1 (en) | Endoprosthesis with stress reducing features | |
US11918752B2 (en) | Flexible and stretch resistant elongate shaft | |
US20230091629A1 (en) | Stent system | |
US20230346577A1 (en) | Anti-migration stent | |
US20220226096A1 (en) | Covered Endoprosthesis with Improved Branch Drainage | |
WO2024091460A1 (en) | Stent system for maintaining patency of a body lumen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220628 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230413 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230418 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230718 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230919 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231212 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231225 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7411800 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |